Peptides Explained

John Garrett

Peptides Explained breaks down the most talked-about peptides and GLP-1 medications in health, fitness, and longevity — including semaglutide, tirzepatide, BPC-157, TB-500, and more.

Hosted by Registered Nurse John Garrett, this podcast explains how these compounds work, why they're popular, what the research shows, and the real risks and side effects — all in plain language.

No bro science. No hype. Just clear, foundational education.

For informational purposes only. Not medical advice.

For Research Peptides;
True-Sciences.com use Pep20 for 20% off
https://www.skool.com/peptides-explained-15

Play

Open in

67 episodes
a few times a week
Avg 20 min
English

Episodes 67

Newest Oldest Longest

All20 Unplayed20 In progress0 Played0

Counted on this page — what you have heard stays on this device, so it is not something the list can be paged by.

Wednesday · 1 hr 5 min· Video
Where Do Peptides Fit in Pain and Recovery? | Dr. Hany Demian
True-Sciences.com use code Pep20 for 20% off your first order Dr. Hany Demian joins John Garrett for a conversation about chronic pain, injury recovery, regenerative medicine, and where peptides may fit in patient care. Drawing on his clinical experience, Dr. Demian discusses how he approaches patients with different needs, why he avoids a "kitchen sink" approach, and why sleep, nutrition, exercise, and careful assessment still matter. They also talk about clinical judgment, patient safety, and situations where peptides may not be appropriate. The conversation includes clinical anecdotes and personal perspectives. These do not establish that a peptide is safe or effective. Evidence for compounds such as BPC-157 and TB-500 remains limited. This episode is for educational purposes and is not individualized medical advice.
Monday · 19 min· Video
BPC-157 Update: HHS Policy, Human Evidence & WADA Status
BPC-157 is back in the compounding-policy conversation—but what does HHS's new notice actually change, and what does the human evidence show? In this revisit, John Garrett looks at BPC-157's proposed biology, the three small published human reports, new clinical-trial registry entries, the FDA advisory committee's recommendation, and HHS's October 30 interim enforcement-discretion policy. The published human record remains small and very low certainty. For BPC-157, the HHS policy identifies the acetate form and specified dosage forms under limited Section 503A circumstances. It is conditional and interim; it does not make BPC-157 FDA-approved, add it to the 503A Bulks List, or establish that it works. We also explain why the anti-doping rules are a separate question. This episode is for informational purposes only and is not medical advice. Research and policy details were checked October 30, 2026; verify current status before publication.
October 28 · 1 hr
Beyond Stem Cells: Secretomes, Cellular Repair & Longevity | Sanjiv Lal
What if the future of regenerative medicine isn't just about stem cells—but the biological messages those cells send? In this episode of Peptides Explained, John Garrett sits down with Sanjiv Lal, founder of Cell Factor and co-founder of Regen Therapy, to explore the emerging science of secretomes, cellular communication, and regenerative medicine. Sanjiv shares his personal journey from pharmaceutical sciences and molecular diagnostics to becoming a patient facing significant health challenges. That experience sparked his interest in cell-free regenerative technologies and the biological signaling systems involved in tissue repair, inflammation, and aging. Together, John and Sanjiv explore: Secretome science: What secretomes are and how they differ from stem cells and exosomes. Cellular communication: How peptides, growth factors, cytokines, and extracellular vesicles influence biological signaling. Cell Factor: Sanjiv's explanation of the technology, manufacturing process, and potential applications. Mitochondrial health: The relationship between cellular energy, inflammation, and biological function. Healthspan vs. lifespan: Why extending healthy, functional years matters as much as extending life. Peptides and longevity: Sanjiv's personal experience with Cell Factor, SS-31, MOTS-c, and other interventions. The future of healthcare: The potential role of preventive medicine, personalized diagnostics, and emerging regenerative technologies. Sanjiv also discusses his own health improvements and his vision for expanding access to regenerative medicine through Regen Therapy and related ventures. The bigger question: Can scientists harness cellular signaling to improve human health, and what clinical evidence will be needed to demonstrate that these approaches are safe and effective? This is a conversation about scientific possibility, innovation, and taking a more active role in long-term health. Learn more: Cell Factor: https://cell.health/ RegenTherapy https://regentherapy.com Important disclaimer: This episode is for educational purposes only and does not constitute medical advice. Cell Factor and the experimental approaches discussed should not be considered proven treatments for kidney disease, diabetes, aging, or other medical conditions. Personal experiences are not controlled clinical evidence. Consult a qualified healthcare professional before making treatment decisions.
October 26 · 14 min· Video
CJC-1295 Deep Dive: What the Human Evidence Actually Shows
True-Sciences.com Use Code Pep20 for 20% off. A careful look at CJC-1295: the growth-hormone pathway, the distinction between DAC and no-DAC naming, what small human studies measured, the terminated Phase 2 trial, current FDA compounding information, the unproven CJC-1295/ipamorelin combination claims, and WADA's 2026 rules. The evidence supports a hormone effect for the long-acting DAC-modified compound; it does not establish the benefits often marketed for consumer products. Educational content only; not medical advice. Snapshot checked October 19, 2026.
October 21 · 44 min· Video
The Silent Killer in Your Kitchen? Seed Oils, Inflammation & What to Cook With Instead with Cherie Calbom
Seed oils may be hiding in more of your everyday foods than you realize. In this episode of Peptides Explained, host John talks with Cherie Calbom, MS—known as the Juice Lady—about seed oils, cooking fats, inflammation, and how to make more informed choices at the grocery store and when dining out.Cherie discusses how common seed oils are processed, why she recommends checking ingredient labels, and which alternatives she uses, including olive oil, avocado oil, coconut oil, ghee, and beef tallow. They also talk about omega-6 and omega-3 balance, cooking with different fats, and practical ways to make food swaps without giving up flavor.The conversation explores the history of seed oils and changing ideas about dietary fat and cholesterol. Cherie shares tips for spotting oils in packaged foods and describes resources for people who want to learn more, including her book The Truth About Seed Oils. Topics include: seed oils, cooking fats, inflammation, omega-6 and omega-3, food labels, nutrition, and healthy cooking.
October 19 · 13 min· Video
Retatrutide: Is It Time to Panic? Lilly's Lawsuits, the Science, and What Happens Next
Eli Lilly is taking legal action against businesses selling products labeled retatrutide. What do the lawsuits actually establish—and what don't they? John Garrett separates pending legal allegations from court findings, reviews the human trial evidence for the investigational triple agonist, and explains why molecular identity, purity, and pharmaceutical equivalence are not interchangeable. We also examine FDA restrictions, consumer safety, and the implications for clinics, vendors, and independent educators. Educational only; not medical or legal advice. Retatrutide is not FDA-approved. Sources: NEJM DOI 10.1056/NEJMoa2301972; FDA unapproved GLP-1 drug concerns; ClinicalTrials.gov NCT05929066 and NCT05882045.
October 14 · 19 min
Can Peptides Protect the Brain From Vascular Damage?
Can peptide biology protect the brain from vascular damage? John follows a question that started with Vesugen into the biology of vascular cognitive impairment—endothelial dysfunction, hypoperfusion, blood-brain-barrier injury, mitochondrial stress, inflammation and neuronal damage. The episode maps Cerebrolysin, SS-31/elamipretide, ARA-290/cibinetide, Semax, Vesugen and GLP-1 receptor agonists onto different points in that cascade, then asks the question that matters: what does the human evidence actually support? Cerebrolysin provides the biggest surprise, with randomized vascular-dementia trials—but still low-certainty evidence. Educational only; not medical advice.
October 12 · 14 min· Video
What the Heck Is Visceral Fat? (And Why People Keep Getting It Wrong)
Everyone keeps calling belly fat "visceral fat." That is not how anatomy works. In this crossover episode, John breaks down the difference between visceral and subcutaneous fat, why visceral adipose tissue matters metabolically, how it is actually measured, what waist circumference can and cannot tell you, and what the evidence says about GLP-1 therapies and tesamorelin.
October 7 · 16 min· Video
Vesugen and Vascular Aging: Interesting Biology or Overhyped Claim?
Vesugen is only three amino acids long: lysine, glutamate, and aspartate — KED. Yet it is promoted as a vascular bioregulator that may support endothelial health and even "rejuvenate" aging blood vessels. In this episode, John Garrett looks at what the endothelial research actually measured, the proposed gene-regulation mechanism, a small human blood-flow report, and the large gap between an interesting cell signal and a proven cardiovascular therapy. No hype. No dismissal. Just the biology, the evidence, and what remains unknown. INSTAGRAM CAPTION Three amino acids. K. E. D. And somehow that became a claim about "rejuvenating" aging blood vessels. Vesugen is one of the more interesting Khavinson bioregulator peptides because there is actual published endothelial-cell research behind the concept. But there is a big difference between: changing a cell marker improving endothelial function and preventing cardiovascular disease. In the new episode of Peptides Explained, I break down the mechanism, the human signal, the evidence gaps, and the question that matters most: Can Vesugen actually make aging blood vessels younger — or is the marketing way ahead of the science? Educational only. Not medical advice. #PeptidesExplained #Vesugen #KEDPeptide #Peptides #Longevity #VascularHealth #EndothelialHealth #CardiovascularHealth #HealthyAging #Biohacking #PeptideScience #MedicalScience
October 5 · 10 min· Video
FLGR-242 Explained: Smarter Follistatin—or Unproven Hype?
FLGR-242 is being called a smarter, longer-acting follistatin. John examines the advertised construct, the activin-sparing and 19-day half-life claims, the difference between pathway evidence and product evidence, and why transformation photos cannot establish pharmacology or safety.
September 30 · 10 min· Video
Follistatin Explained: Can You Really Remove the Muscle-Growth Brake?
Follistatin can bind myostatin—one of the body's major restraints on skeletal-muscle growth. Animal studies are dramatic, and small human gene-therapy studies have produced encouraging signals in serious muscle disease. But is a vial labeled "Follistatin-344" equivalent to the therapy used in those trials? John Garrett explains FST288, FST315, and FST344; the myostatin/activin pathway; the difference between gene therapy and recombinant protein; the evidence for muscle size versus function; and the key safety and product-identity questions. Follistatin is not an FDA-approved muscle-building medication. Educational content only; not medical advice. Explore the free Peptides Explained app: https://app.peptidesexplained.info
September 28 · 15 min· Video
Glutathione: The "Master Antioxidant" — or Master Marketing?
Glutathione gets called the "master antioxidant," and the underlying biology really is important. But does that mean oral supplements, liposomal products or glutathione IVs deliver the sweeping detox, energy, immune and anti-aging benefits often attached to them? John breaks down glutathione biology, the GSH/GSSG cycle, oral human data, NAC, skin-related research and the gap between changing a biomarker and changing a meaningful health outcome. The episode also covers the 2026 FDA warning and recalls involving compounded injectable glutathione and elevated endotoxin levels. The key question: where does established biology end and wellness marketing begin? Educational only. Not medical advice.
September 23 · 13 min· Video
GLP-1 Split Dosing: This Is NOT Microdosing
For more information on Research Peptides go to PeptidesExplained.info/OfflinePeptides Is taking smaller GLP-1 doses multiple times per week actually "microdosing"? Not necessarily. This episode separates split dosing from true dose reduction and explains the pharmacokinetic logic using semaglutide, tirzepatide, and retatrutide. John breaks down half-life, peaks, troughs, total exposure, and why changing the schedule does not automatically mean using less drug. We also examine the major evidence gap: once-weekly dosing has a strong clinical foundation for semaglutide and tirzepatide, while retatrutide remains investigational — and direct randomized evidence showing routine split dosing is superior is not established. Educational only. No individualized dosing protocols are provided.
September 21 · 18 min· Video
Icotyde: The Oral Peptide That Could Change Medicine
Download The Peptide App at ThePeptide.App/Explained For more information on research peptides check out PeptidesExplained.info/OfflinePeptides A peptide…in a pill? Icotyde, or icotrokinra, is an FDA-approved oral peptide designed to block the IL-23 receptor in moderate-to-severe plaque psoriasis. In Phase 3 trials, it produced substantial skin clearance and outperformed an established oral comparator on several key endpoints. But the biggest story may be the delivery platform itself. Peptides usually struggle to survive the digestive tract and reach circulation. Icotyde shows what can happen when medicinal chemistry, structural engineering and extreme receptor potency come together. This episode breaks down what worked, what the safety data show, and what this does—and does not—mean for the future of oral peptides. Educational only. Not medical advice.
September 16 · 17 min· Video
Why Your Favorite Peptides May Never Get a Big Human Trial
If BPC-157, TB-500, KPV, MOTS-C and similar peptides are so interesting, why don't we have giant randomized human trials? This episode looks at the less dramatic—and more important—answer: clinical trials require a sponsor, regulatory strategy, manufacturing package, defined indication, safety program, and a very large amount of money. For old, easily copied, poorly protected, or commercially fragmented compounds, the incentive to fund definitive trials may be weak. John also explains why that does not excuse the evidence gap. "No Phase 3 trial" is not proof that a peptide works. It simply means confidence should remain limited until better evidence exists. Educational only. Not medical advice.
September 14 · 18 min· Video
The Hollywood Trinity Stack: What Happened When I Tried It
Download The Peptide App @ ThePeptide.App/Explained For more info on research peptides visit PeptidesExplained.info/OfflinePeptides John Garrett shares his N=1 experience with the so-called "Trinity Stack"—established TRT, retatrutide, and tesamorelin—combined with resistance training, Zone 2 cardio, high protein intake, creatine, sauna, and cold plunging. The transformation was dramatic. But what likely came from appetite control? What helped preserve muscle? What might the GH/IGF-1 axis have added? And how much credit belongs to the boring fundamentals? This is a candid personal testimony and accessible science breakdown—not a deep dive, a dosing guide, or a warning lecture. John also explains what happened during an eight-week break and why he recently restarted with a goal of reaching 10% body fat. Educational only. Retatrutide remains investigational and is not FDA-approved.
September 9 · 14 min· Video
SNAP-8: Is "Botox in a Bottle" Real?
SNAP-8 is a synthetic cosmetic octapeptide marketed for expression lines and frequently called "Botox in a bottle." John Garrett, RN, breaks down the SNAP-25 and SNARE-complex mechanism, the difference between topical SNAP-8 and injected botulinum toxin, the skin-penetration problem, the Argireline evidence, a small 2024 microneedle combination study, safety, and the limits of the current human data. The mechanism is plausible. The evidence is not strong enough to call it a needle-free Botox equivalent. Educational content only; not medical advice.
September 7 · 23 min· Video
GLP-1 Microdosing: Smart Strategy or the Next Wellness Fad?
Visit peptidesexplained.info for more info and resources For more info on research peptides check out PeptidesExplained.info/OfflinePeptides or email John at john@peptidesexplained.info What exactly is GLP-1 microdosing? Depending on who you ask, it can mean remaining on the starter dose, taking a fraction of that dose, spacing injections farther apart, stepping down after weight loss, or using a tiny amount for food noise and longevity. Those are not the same strategy. John Garrett breaks down the new low-dose semaglutide and tirzepatide data, FDA-approved dose structures, weight-regain research, maintenance questions, side effects, and the major gap between individualized clinical titration and social-media "microdosing" protocols. Educational content only. Not medical advice.
September 2 · 15 min· Video
Thymalin vs Thymogen: Can Thymus Peptides Reverse Immune Aging?
Can a peptide reverse age-related immune decline? Thymalin and Thymogen are often discussed together, but one is a complex calf-thymus extract and the other is the defined dipeptide Glu-Trp. John Garrett explains thymic involution, T-cell biology, proposed mechanisms, the Russian clinical history, limitations of the human evidence, safety, and U.S. regulatory status. The science is interesting. The "immune rejuvenation" and life-extension claims remain unproven. Educational only. Not medical advice.
August 31 · 22 min· Video
What Is Pinealon? Brain Aging, Neuroprotection, and the Evidence
Check out The Peptide App here: thepeptide.app/explained What is Pinealon, and does this three-amino-acid peptide really protect the aging brain? Pinealon—also called EDR or Glu-Asp-Arg—is a synthetic tripeptide associated with the Khavinson bioregulator research program. It is discussed for memory, neuroprotection, oxidative stress, brain aging, and even Alzheimer's disease, but the evidence is much more complicated than the marketing language suggests. John Garrett, examines Pinealon's proposed mechanism, cell and animal research, a newer induced-neuron study, and the PubMed-indexed human reports that are often overlooked. The episode also explains why Pinealon is different from Epitalon, where the human evidence is weak, what remains unknown about brain exposure and long-term safety, and why a plausible mechanism is not the same thing as an established cognitive therapy. Educational content only. Not medical advice.

Showing 1–20 of 67 episodes